Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative transcriptomics in human COPD reveals dysregulated genes uniquely expressed in ferrets.

Respiratory research·2022

Same author

Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties.

Vascular pharmacology·2022

Same author

Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.

The European respiratory journal·2022

Same author

Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission.

Lancet (London, England)·2022

Same author

RETHINCking COPD - Bronchodilators for Symptomatic Tobacco-Exposed Persons with Preserved Lung Function?

The New England journal of medicine·2022

Same author

Association of bronchial steroid inducible methylation quantitative trait loci with asthma and chronic obstructive pulmonary disease treatment response.

Clinical and translational allergy·2022

Same journal

Beyond the 5th percentile: rethinking diagnostic thresholds in pulmonary function testing.

The European respiratory journal·2026

Same journal

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026

Same journal

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026

Same journal

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026

Same journal

Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.

The European respiratory journal·2026

Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 30, 2025

Methodology for Sputum Induction and Laboratory Processing

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Type 2 airway inflammation in COPD.

Francesca Polverino¹, Don D Sin²

¹Pulmonary and Critical Care Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

The European Respiratory Journal

|March 14, 2024

Summary

This summary is machine-generated.

Type 2 inflammation, previously underestimated in chronic obstructive pulmonary disease (COPD), is now recognized as a key driver in about one-third of patients. Targeting this inflammation offers a promising new therapeutic avenue for COPD management.

More Related Videos

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Methods for Detecting Cough and Airway Inflammation in Mice

Methods for Detecting Cough and Airway Inflammation in Mice

Published on: August 2, 2024

Related Experiment Videos

Last Updated: Jun 30, 2025

Methodology for Sputum Induction and Laboratory Processing

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Methods for Detecting Cough and Airway Inflammation in Mice

Methods for Detecting Cough and Airway Inflammation in Mice

Published on: August 2, 2024

Area of Science:

Pulmonary Medicine
Immunology
Respiratory Diseases

Background:

Chronic obstructive pulmonary disease (COPD) affects nearly 400 million people globally, causing significant hospitalization and mortality.
COPD is characterized by airway inflammation, but the role of type 2 inflammation has been historically considered minor compared to asthma.

Purpose of the Study:

To identify key molecules and immune cells involved in type 2 airway inflammation in COPD.
To review recent therapeutic trial outcomes for biologicals targeting type 2 inflammation in COPD.
To explore future directions for developing type 2 immune modulators for COPD treatment.

Main Methods:

Literature review of recent studies on type 2 inflammation in COPD.
Analysis of immune cell populations and molecular pathways implicated in COPD.
Evaluation of clinical trial data for biologic therapies targeting type 2 pathways.

Main Results:

Approximately one-third of COPD patients exhibit significant type 2 inflammation, suggesting it as a crucial disease driver.
The immune cells and molecules involved in COPD-related type 2 immunity may differ from those in severe asthma.
Recent trials of biologics targeting type 2 pathways show potential, though specific efficacy varies.

Conclusions:

Type 2 inflammation is an important, often overlooked, component in a subset of COPD patients.
Targeting type 2 immune pathways represents a viable therapeutic strategy for COPD.
Further research and development of type 2 immune modulators are warranted for effective COPD management.